AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29268948
Drug: Chemotherapy (vinflunine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (vinflunine 320 mg/m2, paclitaxel 175 mg/m2, or 75 mg/m2 docetaxel) every 3 weeks
Trial: 20636964
Drug: Anaesthetic cream
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthetic cream (EMLA) applied to the lower leg for 1.5 hours
Trial: 20636964
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied to the lower leg for 1.5 hours
Trial: 15102391
Drug: Anaesthetic cream
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthetic cream (EMLA)
Trial: 17240783
Drug: Low Glycemic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Glycemic Index (LGI) meal, 2 g/kg body mass CHO, ingested 3 hours prior to exercise
Trial: 17240783
Drug: High Glycemic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Glycemic Index (HGI) meal, 2 g/kg body mass CHO, ingested 3 hours prior to exercise
Trial: 31944084
Drug: Endophytic rhizobacteria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endophytic rhizobacteria treatment
Trial: 30093516
Drug: Enhanced rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced rehabilitation package (patient‐held information workbook, goal‐setting diary, and up to six additional therapy sessions)
Trial: 16824240
Drug: S(+) ketamine
RxNorm normalized name: (S)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+) ketamine (0.05 mg kg‐1, 1.0 mL)
Trial: 16824240
Drug: Fentanyl (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (25 microg, 1.0 mL)
Trial: 16824240
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline (1.0 mL)
Trial: 12865483
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of hypertension in subjects aged 80 years and older
Trial: 6838744
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 2-3.5 ml
Trial: 30786754
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 mg for the first 4 weeks, then force-titrated to 25 mg until week 24)
Trial: 27129007
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of allopurinol (200 mg)
Trial: 27129007
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of allopurinol (200 mg)
Trial: 22650250
Drug: Wireless capsule
RxNorm normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wireless capsule pH‐metry (WC)
Trial: 21048707
Drug: Oral microdose
RxNorm normalized name: LANCET,MICRODOT SAFETY 28G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral microdose of (14)C-labeled acetaminophen (AAP)
Trial: 9484756
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) at a dose of 800 mg/day, then 1200 mg/day
Trial: 7648765
Drug: E3810 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E3810 (20 mg)
Trial: 358021
Drug: Vincamine hydrochloride,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincamine hydrochloride, administered intramuscularly for 10 days
Trial: 358021
Drug: Dihydrogenated ergotoxine
RxNorm normalized name: Dihydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrogenated ergotoxine derivative, administered intramuscularly for 10 days
Trial: 15351795
Drug: Gliclazide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (20 mg/day)
Trial: 15351795
Drug: Nateglinide (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (270 mg/day, 90 mg t.i.d.)
Trial: 11018853
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to ZDV + 3TC therapy (switch arm)
Trial: 8339870
Drug: Verapamil 360
RxNorm normalized name: verapamil 360 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 360 mg daily for 4 weeks
Trial: 3825912
Drug: 300 to
RxNorm normalized name: tenofovir disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 to 400 mg 3‐OHQ orally
Trial: 3825912
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg quinidine base intravenously
Trial: 3825912
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 300 to 400 mg 3‐OHQ orally and 150 mg quinidine base intravenously
Trial: 28549592
Drug: Collaborative pharmacist-physician
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative pharmacist-physician medication therapy management (MTM) program
Trial: 22425375
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (rESWT) - 1500 pulses, 8 Hz, 3 bars, 4 sessions once a week
Trial: 20388647
Drug: Eplerenone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (25 mg every other day to 50 mg daily, adjusted based on serum potassium)
Trial: 16468962
Drug: TAC-SRL2 mg
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAC-SRL2 mg
Trial: 16468962
Drug: TAC-SRL0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC-SRL0.5 mg
Trial: 10961218
Drug: Conventional CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional CT (sequential mode)
Trial: 8928758
Drug: GH (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH (0.3 mg.kg‐1.day‐1 sc)
Trial: 3882269
Drug: Tiapamil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapamil (1 mg/kg followed by 25 micrograms/kg/min over 36 hr)
Trial: 29020467
Drug: Fractional picosecond
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional picosecond 1,064 nm laser plus 4% hydroquinone cream
Trial: 29020467
Drug: 4% hydroquinone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% hydroquinone cream only
Trial: 25900347
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g daily of placebo gel applied topically + periodontal debridement
Trial: 25900347
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g daily of a 15% Mtz benzoate gel applied topically + periodontal debridement
Trial: 25900347
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg Mtz (Flagyl(®)) daily single dose + periodontal debridement
Trial: 20127212
Drug: Subcutaneous indwelling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous indwelling vacuum drainage
Trial: 18540740
Drug: Medication (withdrawn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (withdrawn onto pill-placebo)
Trial: 18540740
Drug: Medication continuation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication continuation
Trial: 7594103
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose sematilide (0.75 then 0.3 mg/min)
Trial: 7594103
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose sematilide (1.5 then 0.6 mg/min)
Trial: 7594103
Drug: Neither low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither low nor high dose sematilide
Trial: 7594103
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose sematilide
Trial: 27841822
Drug: Norepinephrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (10 to 60 μg/min)
Trial: 26231757
Drug: EAT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EAT intervention delivered by dietitians during usual consultations, based on behaviour change counselling methods including motivational interviewing and cognitive-behavioural therapy.
Trial: 26231757
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition providing treatment as usual before switching to EAT intervention.
Trial: 21507143
Drug: Procalcitonin (PCT)
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin (PCT) guidance for antibiotic treatment
Trial: 21507143
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (current guidelines for antibiotic treatment)
Trial: 19476770
Drug: Oral discussion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral discussion and written pamphlet outlining the risks of the procedure
Trial: 19476770
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral dialogue of the surgical risks
Trial: 30999554
Drug: AA mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA mixture containing 3600 mg of arginine, 2200 mg of valine, and 200 mg of serine
Trial: 28678853
Drug: Generic alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic alendronate (Bonmax®) 70 mg/week
Trial: 28678853
Drug: Brand alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brand alendronate (Fosamax®) 70 mg/week
Trial: 23535090
Drug: Combined antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antihistamines and leukotriene antagonists
Trial: 11835741
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO), 3 courses of treatment
Trial: 11835741
Drug: Dehydrating, cortical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dehydrating, cortical steroid and antibiotic therapy (Control)
Trial: 7818588
Drug: Azelastine hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine hydrochloride 8.8 mg
Trial: 7818588
Drug: Azelastine hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine hydrochloride 17.6 mg
Trial: 30110579
Drug: Talazoparib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib (1 mg once daily)
Trial: 30110579
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles)
Trial: 25714598
Drug: Inclacumab (0.03-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclacumab (0.03-20 mg/kg)
Trial: 21349483
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (154 mEq/L, 0.5 ml/kg bolus before contrast, followed by infusion at 1 ml/kg/hour for 6 hours)
Trial: 21349483
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride (0.5 ml/kg bolus before contrast, followed by infusion at 1 ml/kg/hour for 6 hours)
Trial: 18753003
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (0.5-4mg/24h)
Trial: 9602596
Drug: Metoclopramide 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.2 mg kg‐1
Trial: 2667745
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no tamoxifen therapy)
Trial: 31282592
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg on days 2-7) with Itacitinib (200 mg on days 1 and 6)
Trial: 31282592
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg on days 2-9) with Itacitinib (200 mg on days 1 and 9)
Trial: 21831711
Drug: Immediate pre-TURBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate pre-TURBT EMDA mitomycin (40 mg in 100 mL sterile water with 20 mA pulsed electric current for 30 min)
Trial: 19350369
Drug: Manualized behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manualized behavioral treatment including motivational interviewing and cognitive therapy
Trial: 14977161
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg gum
Trial: 14977161
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg gum
Trial: 14977161
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg tablet
Trial: 9244228
Drug: Midodrine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (5 to 10 mg)
Trial: 9244228
Drug: I.V. saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. saline (1 L)
Trial: 27165542
Drug: Acetylic Salicylic
RxNorm normalized name: acetyl salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylic Salicylic Acid (ASA) 500 mg once daily for 12 weeks
Trial: 24840857
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g day(‐1) for 7 days followed by 5 g day(‐1))
Trial: 18608735
Drug: Pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% cream plus NB-UVB
Trial: 14572747
Drug: Bicalutamide 150
RxNorm normalized name: bicalutamide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150 mg in addition to standard care
Trial: 10701823
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (8 mg)
Trial: 3628610
Drug: d-amphetamine 5
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 5 mg/70 kg
Trial: 3628610
Drug: d-amphetamine 10
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 10 mg/70 kg
Trial: 24139558
Drug: Placebo (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (isotonic saline 1.25 ml/kg/doses intravenously every 12 hours for 48 hours)
Trial: 22337227
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil (1.1 g/d n-3 LCPUFA)
Trial: 20410410
Drug: Low-dose ungated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ungated MDCT
Trial: 15955616
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen (CEE) + 2.5 mg medroxyprogesterone acetate (MPA)
Trial: 15955616
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol valerate
Trial: 12217947
Drug: Baclofen (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (15 mg/day for the first 3 days, then 30 mg/day for 27 days)
Trial: 8607000
Drug: Chronic CPAP
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic CPAP therapy (Continuous Positive Airway Pressure)
Trial: 7386493
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone
Trial: 31704188
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol at 0.25 μg, 3 times weekly with ACEI or ARB
Trial: 30945478
Drug: High Concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Concentration Oxygen Therapy (HCOT)
Trial: 30945478
Drug: Titrated Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated Oxygen Therapy (TOT)
Trial: 27020489
Drug: 200 μg sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg sublingual misoprostol with cervical laminaria
Trial: 27020489
Drug: 400 μg sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg sublingual misoprostol without laminaria
Trial: 23594463
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 1.6 million units thrice-daily for 10 days
Trial: 23594463
Drug: Amoxicillin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1,000 mg thrice-daily for 10 days
Trial: 17666194
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with telmisartan and ramipril (an ACE inhibitor)
Trial: 11084548
Drug: High-dose intravaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravaginal misoprostol (600 microg vaginally)
Trial: 9487348
Drug: Colistin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin (2 MU tds intravenously) with a second anti-pseudomonal antibiotic (dual therapy)
Trial: 8368227
Drug: Pamidronate (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (all doses)
Trial: 30693611
Drug: Project-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Project-based treatment (20 hours over 6 weeks)
Trial: 28800382
Drug: Cotrimoxazole prophylaxis
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole prophylaxis (200 mg of SMX/40 mg of TMP once daily)
Trial: 28800382
Drug: Regimens of
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimens of 30 mg kg-1 of SMX and 6 mg kg-1 of TMP for the 5-10 kg group and 25 mg kg-1 of SMX and 5 mg kg-1 of TMP for the 10-15 kg group
Trial: 23969513
Drug: Pertuzumab, trastuzumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertuzumab, trastuzumab, and docetaxel combination
Trial: 15541448
Drug: bivalent HPV-16/18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent HPV-16/18 L1 virus-like particle vaccine
Trial: 8034784
Drug: SofScale calculus
RxNorm normalized name: Anamirta cocculus fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SofScale calculus scaling gel
Trial: 2659679
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of heat‐killed Leishmania mexicana amazonensis promastigotes and viable BCG
Trial: 2659679
Drug: Meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine antimoniate chemotherapy
Trial: 2659679
Drug: Combined immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined immunotherapy
Trial: 31711041
Drug: Mézières method
RxNorm normalized name: Rezipres
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mézières method postural therapy (60 minutes, 2-3 sessions per week for 24 weeks)
Trial: 31711041
Drug: Mézières method
RxNorm normalized name: Rezipres
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mézières method postural therapy
Trial: 25535985
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg weekly (group A, 159 patients)
Trial: 25535985
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg bi-weekly (group B, 164 patients)
Trial: 25535985
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg weekly (group A)
Trial: 25535985
Drug: Etanercept half-dose
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept half-dose regimen
Trial: 31135225
Drug: Synbiotic supplement
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplement (109 CFU/day) for 10 weeks
Trial: 23339584
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) - up to 12 sessions in addition to usual care
Trial: 16984012
Drug: Org 9426
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 9426 (0.6 mg x kg(‐1))
Trial: 16984012
Drug: Org 9426
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 9426 (0.9 mg x kg(‐1))
Trial: 19863739
Drug: Vecuronium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.1 mg x kg(‐1))
Trial: 16984012
Drug: Org 9426
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 9426 (0.15 mg x kg(‐1))